Sensorion Announces its Participation in the World Congress of Audiology in September 2024 in Paris and will Lead a Symposium on Medical Advances in the Field of Hearing Loss

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the 36^th World Congress of Audiology (WCA), taking place in Paris, France, on September 19-22, 2024.

On this occasion, Sensorion will host a symposium on September 20, 2024, at 12.30pm CET, entitled:

“Are we at the Dawn of a Hearing Loss Revolution?”

This event will be hosted by Professor Natalie Loundon ENT Surgeon in the pediatric Hospital Necker-Enfants malades in Paris, France. The symposium will comprise three sessions:

• 1^st Session: Hearing Preservation: Relevant Medical Progress in Cisplatin-Induced Ototoxicity and the Loss of the Residual Hearing following Cochlear Implantation

This session will focus on the therapeutic advances in hearing preservation associated with Cisplatin-Induced Ototoxicity and following cochlear implantation. Professor Yann Nguyen (ENT Surgeon, Hôpital de la Pitié Salpêtrière, Paris, France) and Professor Stephen O'Leary (Head of Otolaryngology at the University of Melbourne, Melbourne, Australia) will co-present this session.

• 2^nd Session: Gene therapy: A Ray of Hope for Congenital Hearing Disorders

This session will address gene therapy applied to patients suffering from congenital profound deafness and will be presented by Professor Catherine Birman (Otorhinolaryngologist, Director of the Sydney Cochlear Implant Centre, Sydney, Australia).

• 3^rd Session: Conclusion: What Does the Future Hold for these New Therapies?

This session will be led by Professor Natalie Loundon (Pediatric otorhinolaryngologist, Director of the Cochlear Implant and Audiology Unit, Necker-Enfants malades, Paris, France) and will address the impact these new therapies will have on patient management, followed by a question-and-answer session.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.